Revisiting antibody-drug conjugates and their predictive biomarkers in platinum-resistant ovarian cancer

Unlocking the potential of antibody–drug conjugates for cancer therapy

(2021) Joshua Z. Drago et al.   Nature Reviews Clinical Oncology

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

(2020) David J. Straus et al.   BLOOD

Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients

(2020) Alessandra Battaglia et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

(2020) David M. O'Malley et al.   GYNECOLOGIC ONCOLOGY

Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study

(2020) Molly Brewer et al.   GYNECOLOGIC ONCOLOGY

Is HE4 Superior over CA-125 in the Follow-up of Patients with Epithelial Ovarian Cancer?

(2020) Khalid El Bairi et al.   CURRENT DRUG TARGETS

Antibody-drug conjugates for the treatment of ovarian cancer

(2020) Corinne A. Calo et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer

(2020) Hope S Rugo et al.   Future Oncology

Effect of automated TIL quantification in early-stage melanoma on accuracy of standard T staging using AJCC guidelines.

(2020) Michael Moore et al.   JOURNAL OF CLINICAL ONCOLOGY

Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study

(2020) Reinhard Dummer et al.   EUROPEAN JOURNAL OF CANCER

Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study

(2020) Erika Hamilton et al.   GYNECOLOGIC ONCOLOGY

Nanotechnology-Based Cisplatin Intracellular Delivery to Enhance Chemo-Sensitivity of Ovarian Cancer

(2020) Barbara Bortot et al.   International Journal of Nanomedicine

Structure of human DPEP3 in complex with the SC-003 antibody Fab fragment reveals basis for lack of dipeptidase activity

(2020) Kristyn Hayashi et al.   JOURNAL OF STRUCTURAL BIOLOGY

Antibody-Drug Conjugates: A Promising Novel Therapy for the Treatment of Ovarian Cancer

(2020) Aranzazu Manzano et al.   Cancers

Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics

(2020) Xiao Han et al.   ACCOUNTS OF CHEMICAL RESEARCH

836P Safety and efficacy of XMT-1536 in ovarian cancer: A subgroup analysis from the phase I expansion study of XMT-1536, a NaPi2b antibody-drug conjugate

(2020) E.P. Hamilton et al.   ANNALS OF ONCOLOGY

Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial

(2020) Leisha A Emens et al.   LANCET ONCOLOGY

Insights Into the Role of Mesothelin as a Diagnostic and Therapeutic Target in Ovarian Carcinoma

(2020) Jiayu Shen et al.   Frontiers in Oncology

Role of biomarkers for early detection of ovarian cancer recurrence

(2020) Pierluigi Giampaolino et al.   Gland Surgery

EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma

(2020) Kyriaki Tzogani et al.   ONCOLOGIST

Acquired Resistance to Antibody-Drug Conjugates

(2019) Denis Collins et al.   Cancers

Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)

(2019) Franck Morschhauser et al.   Lancet Haematology

Serum folate receptor α (sFR) in ovarian cancer diagnosis and surveillance

(2019) Batoul Farran et al.   Cancer Medicine

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

(2019) Aditya Bardia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial

(2019) Johann S de Bono et al.   LANCET ONCOLOGY

Antibody-Drug Conjugate-Based Therapeutics: State of the Science

(2019) Michael J Birrer et al.   JNCI-Journal of the National Cancer Institute

Mechanisms of Chemotherapy-Induced Peripheral Neuropathy

(2019) Renata Zajączkowska et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†

(2019) N Colombo et al.   ANNALS OF ONCOLOGY

Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index

(2019) Steven Coats et al.   CLINICAL CANCER RESEARCH

Thrombotic events induce the worse prognosis in ovarian carcinomas and frequently develop in ovarian clear cell carcinoma

(2019) Kazuki Takasaki et al.   International Journal of Clinical Oncology

Phase 1 dose escalation study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC), in patients (pts) with solid tumors likely to express NaPi2b.

(2019) Anthony W. Tolcher et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 2 trial of tisotumab vedotin in platinum-resistant ovarian cancer (innovaTV 208).

(2019) Haider Mahdi et al.   JOURNAL OF CLINICAL ONCOLOGY

A tumor-targeted immune checkpoint blocker

(2019) Yuhan Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer Patients

(2019) David E. Gerber et al.   CLINICAL CANCER RESEARCH

Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives

(2019) Eric Pujade-Lauraine et al.   JOURNAL OF CLINICAL ONCOLOGY

992OFORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)

(2019) K Moore et al.   ANNALS OF ONCOLOGY

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2019) Laurie H. Sehn et al.   JOURNAL OF CLINICAL ONCOLOGY

Antibody-Drug Conjugates: A Comprehensive Review

(2019) Puregmaa Khongorzul et al.   MOLECULAR CANCER RESEARCH

Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study

(2019) Richard F. Schlenk et al.   JOURNAL OF CLINICAL ONCOLOGY

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

(2019) Sagar Lonial et al.   LANCET ONCOLOGY

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

(2019) Shanu Modi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study

(2018) S Banerjee et al.   ANNALS OF ONCOLOGY

Modulation of Macropinocytosis-Mediated Internalization Decreases Ocular Toxicity of Antibody–Drug Conjugates

(2018) Hui Zhao et al.   CANCER RESEARCH

Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study

(2018) Hagop Kantarjian et al.   LANCET ONCOLOGY

Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial

(2018) Sara A Hurvitz et al.   LANCET ONCOLOGY

Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells

(2018) Guangmin Li et al.   MOLECULAR CANCER THERAPEUTICS

Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase 3 ALFA-0701 trial

(2018) Juliette Lambert et al.   HAEMATOLOGICA

Phase Ib study of anti-mesothelin antibody drug conjugate anetumab ravtansine in combination with pegylated liposomal doxorubicin in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.

(2018) Iurie Bulat et al.   JOURNAL OF CLINICAL ONCOLOGY

Treating Tissue Factor-Positive Cancers With Antibody-Drug Conjugates That Do Not Affect Blood Clotting

(2018) Jan-Willem Theunissen et al.   MOLECULAR CANCER THERAPEUTICS

Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine

(2018) Ursula A Matulonis et al.   CLINICAL CANCER RESEARCH

Ocular Toxicity of Mirvetuximab

(2018) Eleonora Corbelli et al.   CORNEA

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

(2018) Steven Horwitz et al.   LANCET

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

(2018) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Peritoneal dissemination of ovarian cancer: role of MUC16-mesothelin interaction and implications for treatment

(2017) Ricardo Coelho et al.   Expert Review of Anticancer Therapy

Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine

(2017) Lainie P. Martin et al.   GYNECOLOGIC ONCOLOGY

Expression of Tissue Factor in Epithelial Ovarian Carcinoma Is Involved in the Development of Venous Thromboembolism

(2017) Manabu Sakurai et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads

(2017) Joanna C. Masters et al.   INVESTIGATIONAL NEW DRUGS

Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study

(2017) Kathleen N. Moore et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study

(2017) Edith A. Perez et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

(2017) Ian E Krop et al.   LANCET ONCOLOGY

Inhibition of Megakaryocyte Differentiation by Antibody–Drug Conjugates (ADCs) is Mediated by Macropinocytosis: Implications for ADC-induced Thrombocytopenia

(2017) Hui Zhao et al.   MOLECULAR CANCER THERAPEUTICS

A Potential Mechanism for ADC-Induced Neutropenia: Role of Neutrophils in Their Own Demise

(2017) Hui Zhao et al.   MOLECULAR CANCER THERAPEUTICS

Correlation Between Tumor Mesothelin Expression and Serum Mesothelin in Patients with Epithelial Ovarian Carcinoma: A Potential Noninvasive Biomarker for Mesothelin-targeted Therapy

(2017) Tatsuya Hanaoka et al.   Molecular Diagnosis & Therapy

Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer

(2017) Ruogu Qi et al.   Nature Communications

Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study

(2017) Hagop M Kantarjian et al.   Lancet Haematology

Mesothelin as a biomarker for ovarian carcinoma: a meta-analysis

(2016) KRISTIAN MADEIRA et al.   ANAIS DA ACADEMIA BRASILEIRA DE CIENCIAS

Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer

(2016) J. F. Liu et al.   ANNALS OF ONCOLOGY

Combining antibody–drug conjugates and immune-mediated cancer therapy: What to expect?

(2016) Hans-Peter Gerber et al.   BIOCHEMICAL PHARMACOLOGY

Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer

(2016) Alice Bergamini et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Linkers Having a Crucial Role in Antibody–Drug Conjugates

(2016) Jun Lu et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial

(2016) Sergio Amadori et al.   JOURNAL OF CLINICAL ONCOLOGY

CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children’s Oncology Group Trial AAML0531

(2016) Jessica A. Pollard et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer

(2016) C. D. Weekes et al.   MOLECULAR CANCER THERAPEUTICS

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

(2016) Hagop M. Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer

(2016) Khalid El Bairi et al.   CELLULAR ONCOLOGY

Targeting folate receptor alpha for cancer treatment

(2016) Anthony Cheung et al.   Oncotarget

Folate Receptor Alpha Expression in Platinum Resistant/Refractory Ovarian Carcinomas and Primary Endocervical Adenocarcinomas

(2016) Lisa A. Rubinsak et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models

(2016) Jose F. Ponte et al.   NEOPLASIA

Current methods for the synthesis of homogeneous antibody–drug conjugates

(2015) Alicja M. Sochaj et al.   BIOTECHNOLOGY ADVANCES

Understanding the Unique Attributes of MUC16 (CA125): Potential Implications in Targeted Therapy

(2015) S. Das et al.   CANCER RESEARCH

Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody-Drug Conjugate as a Therapeutic for Non-Small Cell Lung and Ovarian Cancers

(2015) K. Lin et al.   CLINICAL CANCER RESEARCH

Antibody-targeted drugs and drug resistance—Challenges and solutions

(2015) LeeRon Shefet-Carasso et al.   DRUG RESISTANCE UPDATES

Serum folate receptor alpha as a biomarker for ovarian cancer: Implications for diagnosis, prognosis and predicting its local tumor expression

(2015) Akira Kurosaki et al.   INTERNATIONAL JOURNAL OF CANCER

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

(2015) Craig H Moskowitz et al.   LANCET

IMGN853, a Folate Receptor-  (FR )-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FR -Expressing Tumors

(2015) O. Ab et al.   MOLECULAR CANCER THERAPEUTICS

Tumor Cells Chronically Treated with a Trastuzumab-Maytansinoid Antibody-Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments

(2015) F. Loganzo et al.   MOLECULAR CANCER THERAPEUTICS

Tissue Factor: Old and New Links with Cancer Biology

(2015) Henri Versteeg   SEMINARS IN THROMBOSIS AND HEMOSTASIS

P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: A review

(2015) Hossam M. Abdallah et al.   Journal of Advanced Research

Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study

(2014) M Köbel et al.   BRITISH JOURNAL OF CANCER

The folate receptor as a rational therapeutic target for personalized cancer treatment

(2014) Yehuda G. Assaraf et al.   DRUG RESISTANCE UPDATES

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

(2014) Eric Pujade-Lauraine et al.   JOURNAL OF CLINICAL ONCOLOGY

Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531

(2014) Alan S. Gamis et al.   JOURNAL OF CLINICAL ONCOLOGY

MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress

(2014) Mildred Felder et al.   Molecular Cancer

An Antimesothelin-Monomethyl Auristatin E Conjugate with Potent Antitumor Activity in Ovarian, Pancreatic, and Mesothelioma Models

(2014) S. J. Scales et al.   MOLECULAR CANCER THERAPEUTICS

Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates

(2014) Dowdy Jackson et al.   PHARMACEUTICAL RESEARCH

Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients

(2013) F. Leung et al.   CLINICAL BIOCHEMISTRY

Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy

(2013) E. Despierre et al.   GYNECOLOGIC ONCOLOGY

Tumour expresion of tissue factor and tissue factor pathway inhibitor in ovarian cancer- relationship with venous thrombosis risk

(2013) Feras Abu Saadeh et al.   THROMBOSIS RESEARCH

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

The relationship between tissue factor and cancer progression: insights from bench and bedside

(2011) Y. W. van den Berg et al.   BLOOD

Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor

(2011) Emiliano Cocco et al.   CLINICAL & EXPERIMENTAL METASTASIS

In Silico Analysis and Immunohistochemical Characterization of NaPi2b Protein Expression in Ovarian Carcinoma With Monoclonal Antibody Mx35

(2011) Ibere Cauduro Soares et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

Ovarian cancer

(2009) Bryan T Hennessy et al.   LANCET

A Binding Domain on Mesothelin for CA125/MUC16

(2008) Osamu Kaneko et al.   JOURNAL OF BIOLOGICAL CHEMISTRY